RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages

RRx-001 is a pleiotropic anticancer agent in phase III clinical trials, which polarizes tumor-associated macrophages from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype. One of the ways in which tumors promote M2 polarization and evade macrophage-mediated destruction is through upre...

Descripción completa

Detalles Bibliográficos
Autor principal: Cabrales, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370857/
https://www.ncbi.nlm.nih.gov/pubmed/30738349
http://dx.doi.org/10.1016/j.tranon.2018.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370857/
https://www.ncbi.nlm.nih.gov/pubmed/30738349
http://dx.doi.org/10.1016/j.tranon.2018.12.001

Ejemplares similares